跳至主要内容
临床试验/NCT02365246
NCT02365246招募中2 期

Interventional Trial With IgE-specific Immunoadsorption in Severe Atopic Dermatitis. Interventional Trial With IgE-specific Immunoadsorption in Severe Atopic Dermatitis.

Universitaire Ziekenhuizen KU Leuven1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2014年8月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
入组人数
15
试验地点
1
主要终点
clinical improvement (The improvement of Atopic dermatitis will be evaluated with different scales including SCORAD, EASI, LIS, DLQI)

研究概览

简要总结

Removal of IgE through adsorption of IgE on a specially designed column after apheresis of blood has the potential to improve the severity of atopic dermatitis.

In this study the investigators will treat patients with a severe form of Atopic dermatitis not responding or having to much side effects to systemic imunosuppressive treatment with this modality.

详细描述

Patients will be treated with immunoadsorption on 4 consecutive days week 1 and three consecutive days week 5 and week 9.

The clinical improvement and histological and serological tests will be evaluated.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adults (> 18 year) with severe atopic dermatitis (objective SCORAD > 40)
  • •Who's AD is persistent and stable since more than 1 year
  • •Who signed the informed consent
  • •Who are not pregnant or do not plan to become pregnant, during the immunoadsorption treatment
  • •Who were treated in the recent past with phototherapy or immunosuppressive therapy ( one or more : cyclosporin A, methotrexate , azathioprine , mycophenolate , systemic corticosteroids ) and where this therapy was not sufficiently helpful, had unacceptable side effects or are contraindicated

排除标准

  • •Patients who did not give an informed consent.
  • •Patients with mild or moderate AD.
  • •Patients with severe AD improving with, and tolerating, standard therapy (including phototherapy, short periods of corticosteroids, the above mentioned immunosuppressive therapies ) and having no contra-indications for these therapies
  • •Pregnant women and female patients willing to become pregnant during the planned period of treatment or immediately after.
  • •Having contra-indications for immunoadsorption:
  • •Patients with a known allergy for the material used during immunoadsorption.
  • •Severe cardiovascular diseases.
  • •Severe bleeding during anticoagulation .
  • •Treated with ACE-inhibitors.
  • •Patients younger than18 years.
  • •Having a malignant disease not under remission

研究组 & 干预措施

immunoadsorption group

Experimental

All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :

干预措施: immunoadsorptions with an IgE-specific adsorption column (Device)

结局指标

主要结局

clinical improvement (The improvement of Atopic dermatitis will be evaluated with different scales including SCORAD, EASI, LIS, DLQI)

时间窗: one year

The improvement of Atopic dermatitis will be evaluated with different scales including SCORAD, EASI, LIS, DLQI

次要结局

  • histological improvement and IgE tissue levels(one year)
  • Correlation between the therapeutic response and serum markers of disease activity .(one year)
  • Effect of the treatment on positivity of skin prick tests.(one year)
  • Evaluation of length of improvement(one year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验